Liver sharing and organ procurement organization performance

Sommer E. Gentry, Eric K. H. Chow, Allan Massie, Xun Luo, David Zaun, Jon J. Snyder, Ajay K. Israni, Bert Kasiske, Dorry L. Segev – 31 December 2014 – Whether the liver allocation system shifts organs from better performing organ procurement organizations (OPOs) to poorer performing OPOs has been debated for many years. Models of OPO performance from the Scientific Registry of Transplant Recipients make it possible to study this question in a data‐driven manner.

Prevalence of psychological problems and associated transplant‐related variables at different time periods after liver transplantation

Coby Annema, Petrie F. Roodbol, Roy E. Stewart, Robert J. Porte, Adelita V. Ranchor – 30 December 2014 – After liver transplantation, recipients often experience psychological problems that are influenced by demographic, personal, and transplant‐related variables. However, because previous studies have mostly reported on psychological problems and their influencing factors in the first years after transplantation, less is known about their prevalence and influence in the long run.

Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats

Shao‐Jung Hsu, Fa‐Yauh Lee, Sun‐Sang Wang, I‐Fang Hsin, Te‐Yueh Lin, Hui‐Chun Huang, Ching‐Chih Chang, Chiao‐Lin Chuang, Hsin‐Ling Ho, Han‐Chieh Lin, Shou‐Dong Lee – 29 December 2014 – Portal hypertension (PH), a pathophysiological derangement of liver cirrhosis, is characterized by hyperdynamic circulation, angiogenesis, and portosystemic collaterals. These may lead to lethal complications, such as variceal bleeding. Caffeine has been noted for its effects on liver inflammation, fibrogenesis, and vasoreactiveness.

Ubiquitin‐specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor‐interacting protein 12 and promotes hepatocellular carcinoma progression

Jia‐Bin Cai, Guo‐Ming Shi, Zhao‐Ru Dong, Ai‐Wu Ke, Hong‐Hui Ma, Qiang Gao, Zao‐Zhuo Shen, Xiao‐Yong Huang, Hao Chen, Ding‐Dang Yu, Li‐Xin Liu, Peng‐Fei Zhang, Chi Zhang, Mei‐Yu Hu, Liu‐Xiao Yang, Ying‐Hong Shi, Xiao‐Ying Wang, Zhen‐Bin Ding, Shuang‐Jian Qiu, Hui‐Chuan Sun, Jian Zhou, Yujiang G. Shi, Jia Fan – 29 December 2014 – The prognosis for hepatocellular carcinoma (HCC) remains dismal in terms of overall survival (OS), and its molecular pathogenesis has not been completely defined.

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

Xavier Forns, Michael Charlton, Jill Denning, John G. McHutchison, William T. Symonds, Diana Brainard, Theo Brandt‐Sarif, Paul Chang, Valerie Kivett, Lluís Castells, Martín Prieto, Robert J. Fontana, Thomas F. Baumert, Audrey Coilly, Maria Carlota Londoño, François Habersetzer – 29 December 2014 – Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is associated with accelerated progression of liver disease, frequently leading to graft loss and early death.

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

Arun J. Sanyal, Scott L. Friedman, Arthur J. McCullough, Lara Dimick‐Santos – 29 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality.

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

Arun J. Sanyal, Scott L. Friedman, Arthur J. McCullough, Lara Dimick‐Santos – 29 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality.

Subscribe to